Overview

* Ardelyx Q2 2025 revenue grows 33% yr/yr to $97.7 mln

* Co raises 2025 IBSRELA sales forecast to $250-$260 mln

* Ardelyx ( ARDX ) ends Q2 with $238.5 mln in cash and investments

Outlook

* Company raises 2025 IBSRELA net sales revenue expectations to $250-$260 mln

* Ardelyx ( ARDX ) confident in XPHOZAH growth for remainder of 2025

Result Drivers

* IBSRELA SALES GROWTH - IBSRELA net sales increased 84% yr/yr and 46% qtr/qtr, driven by strategic commercial execution and high demand

* XPHOZAH DEMAND - XPHOZAH net sales revenue increased 27% qtr/qtr, driven by growing demand among healthcare providers

* REVENUE INCREASE - Total revenue grew 33% yr/yr, attributed to increased IBSRELA and XPHOZAH sales

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $90.08

Product mln

Sales

Q2 EPS -$0.08

Q2 Net -$19.08

Income mln

Q2 $99.65

Operatin mln

g

Expenses

Q2 -$14.40

Operatin mln

g Income

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)